Practical approaches to evaluating and optimizing brain exposure in early drug discovery
Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormone...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Freeman, Burgess B. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles - Jose, Ajay ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:182 ; year:2019 ; day:15 ; month:11 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ejmech.2019.111643 |
|---|
| Katalog-ID: |
ELV048263524 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV048263524 | ||
| 003 | DE-627 | ||
| 005 | 20230626021530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200108s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2019.111643 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000788.pica |
| 035 | |a (DE-627)ELV048263524 | ||
| 035 | |a (ELSEVIER)S0223-5234(19)30777-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 42.00 |2 bkl | ||
| 100 | 1 | |a Freeman, Burgess B. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Practical approaches to evaluating and optimizing brain exposure in early drug discovery |
| 264 | 1 | |c 2019transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. | ||
| 520 | |a Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. | ||
| 650 | 7 | |a Brain |2 Elsevier | |
| 650 | 7 | |a Free drug hypothesis |2 Elsevier | |
| 650 | 7 | |a BBB |2 Elsevier | |
| 650 | 7 | |a Penetration |2 Elsevier | |
| 650 | 7 | |a CNS |2 Elsevier | |
| 650 | 7 | |a Drug design |2 Elsevier | |
| 650 | 7 | |a Pharmacokinetics |2 Elsevier | |
| 700 | 1 | |a Yang, Lei |4 oth | |
| 700 | 1 | |a Rankovic, Zoran |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Jose, Ajay ELSEVIER |t Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000457477 |
| 773 | 1 | 8 | |g volume:182 |g year:2019 |g day:15 |g month:11 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejmech.2019.111643 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 42.00 |j Biologie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 182 |j 2019 |b 15 |c 1115 |h 0 | ||
| author_variant |
b b f bb bbf |
|---|---|
| matchkey_str |
freemanburgessbyangleirankoviczoran:2019----:rciaapoceteautnadpiiigriepsr |
| hierarchy_sort_str |
2019transfer abstract |
| bklnumber |
42.00 |
| publishDate |
2019 |
| allfields |
10.1016/j.ejmech.2019.111643 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000788.pica (DE-627)ELV048263524 (ELSEVIER)S0223-5234(19)30777-9 DE-627 ger DE-627 rakwb eng 570 540 VZ BIODIV DE-30 fid 42.00 bkl Freeman, Burgess B. verfasserin aut Practical approaches to evaluating and optimizing brain exposure in early drug discovery 2019transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. Brain Elsevier Free drug hypothesis Elsevier BBB Elsevier Penetration Elsevier CNS Elsevier Drug design Elsevier Pharmacokinetics Elsevier Yang, Lei oth Rankovic, Zoran oth Enthalten in Elsevier Science Jose, Ajay ELSEVIER Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles 2018 Amsterdam [u.a.] (DE-627)ELV000457477 volume:182 year:2019 day:15 month:11 pages:0 https://doi.org/10.1016/j.ejmech.2019.111643 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 42.00 Biologie: Allgemeines VZ AR 182 2019 15 1115 0 |
| spelling |
10.1016/j.ejmech.2019.111643 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000788.pica (DE-627)ELV048263524 (ELSEVIER)S0223-5234(19)30777-9 DE-627 ger DE-627 rakwb eng 570 540 VZ BIODIV DE-30 fid 42.00 bkl Freeman, Burgess B. verfasserin aut Practical approaches to evaluating and optimizing brain exposure in early drug discovery 2019transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. Brain Elsevier Free drug hypothesis Elsevier BBB Elsevier Penetration Elsevier CNS Elsevier Drug design Elsevier Pharmacokinetics Elsevier Yang, Lei oth Rankovic, Zoran oth Enthalten in Elsevier Science Jose, Ajay ELSEVIER Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles 2018 Amsterdam [u.a.] (DE-627)ELV000457477 volume:182 year:2019 day:15 month:11 pages:0 https://doi.org/10.1016/j.ejmech.2019.111643 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 42.00 Biologie: Allgemeines VZ AR 182 2019 15 1115 0 |
| allfields_unstemmed |
10.1016/j.ejmech.2019.111643 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000788.pica (DE-627)ELV048263524 (ELSEVIER)S0223-5234(19)30777-9 DE-627 ger DE-627 rakwb eng 570 540 VZ BIODIV DE-30 fid 42.00 bkl Freeman, Burgess B. verfasserin aut Practical approaches to evaluating and optimizing brain exposure in early drug discovery 2019transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. Brain Elsevier Free drug hypothesis Elsevier BBB Elsevier Penetration Elsevier CNS Elsevier Drug design Elsevier Pharmacokinetics Elsevier Yang, Lei oth Rankovic, Zoran oth Enthalten in Elsevier Science Jose, Ajay ELSEVIER Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles 2018 Amsterdam [u.a.] (DE-627)ELV000457477 volume:182 year:2019 day:15 month:11 pages:0 https://doi.org/10.1016/j.ejmech.2019.111643 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 42.00 Biologie: Allgemeines VZ AR 182 2019 15 1115 0 |
| allfieldsGer |
10.1016/j.ejmech.2019.111643 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000788.pica (DE-627)ELV048263524 (ELSEVIER)S0223-5234(19)30777-9 DE-627 ger DE-627 rakwb eng 570 540 VZ BIODIV DE-30 fid 42.00 bkl Freeman, Burgess B. verfasserin aut Practical approaches to evaluating and optimizing brain exposure in early drug discovery 2019transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. Brain Elsevier Free drug hypothesis Elsevier BBB Elsevier Penetration Elsevier CNS Elsevier Drug design Elsevier Pharmacokinetics Elsevier Yang, Lei oth Rankovic, Zoran oth Enthalten in Elsevier Science Jose, Ajay ELSEVIER Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles 2018 Amsterdam [u.a.] (DE-627)ELV000457477 volume:182 year:2019 day:15 month:11 pages:0 https://doi.org/10.1016/j.ejmech.2019.111643 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 42.00 Biologie: Allgemeines VZ AR 182 2019 15 1115 0 |
| allfieldsSound |
10.1016/j.ejmech.2019.111643 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000788.pica (DE-627)ELV048263524 (ELSEVIER)S0223-5234(19)30777-9 DE-627 ger DE-627 rakwb eng 570 540 VZ BIODIV DE-30 fid 42.00 bkl Freeman, Burgess B. verfasserin aut Practical approaches to evaluating and optimizing brain exposure in early drug discovery 2019transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. Brain Elsevier Free drug hypothesis Elsevier BBB Elsevier Penetration Elsevier CNS Elsevier Drug design Elsevier Pharmacokinetics Elsevier Yang, Lei oth Rankovic, Zoran oth Enthalten in Elsevier Science Jose, Ajay ELSEVIER Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles 2018 Amsterdam [u.a.] (DE-627)ELV000457477 volume:182 year:2019 day:15 month:11 pages:0 https://doi.org/10.1016/j.ejmech.2019.111643 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 42.00 Biologie: Allgemeines VZ AR 182 2019 15 1115 0 |
| language |
English |
| source |
Enthalten in Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles Amsterdam [u.a.] volume:182 year:2019 day:15 month:11 pages:0 |
| sourceStr |
Enthalten in Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles Amsterdam [u.a.] volume:182 year:2019 day:15 month:11 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Biologie: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Brain Free drug hypothesis BBB Penetration CNS Drug design Pharmacokinetics |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |
| authorswithroles_txt_mv |
Freeman, Burgess B. @@aut@@ Yang, Lei @@oth@@ Rankovic, Zoran @@oth@@ |
| publishDateDaySort_date |
2019-01-15T00:00:00Z |
| hierarchy_top_id |
ELV000457477 |
| dewey-sort |
3570 |
| id |
ELV048263524 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV048263524</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626021530.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200108s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejmech.2019.111643</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000788.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV048263524</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0223-5234(19)30777-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Freeman, Burgess B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Practical approaches to evaluating and optimizing brain exposure in early drug discovery</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Brain</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Free drug hypothesis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BBB</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Penetration</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CNS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug design</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacokinetics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Lei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rankovic, Zoran</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Jose, Ajay ELSEVIER</subfield><subfield code="t">Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000457477</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:182</subfield><subfield code="g">year:2019</subfield><subfield code="g">day:15</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejmech.2019.111643</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.00</subfield><subfield code="j">Biologie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">182</subfield><subfield code="j">2019</subfield><subfield code="b">15</subfield><subfield code="c">1115</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Freeman, Burgess B. |
| spellingShingle |
Freeman, Burgess B. ddc 570 fid BIODIV bkl 42.00 Elsevier Brain Elsevier Free drug hypothesis Elsevier BBB Elsevier Penetration Elsevier CNS Elsevier Drug design Elsevier Pharmacokinetics Practical approaches to evaluating and optimizing brain exposure in early drug discovery |
| authorStr |
Freeman, Burgess B. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000457477 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 540 VZ BIODIV DE-30 fid 42.00 bkl Practical approaches to evaluating and optimizing brain exposure in early drug discovery Brain Elsevier Free drug hypothesis Elsevier BBB Elsevier Penetration Elsevier CNS Elsevier Drug design Elsevier Pharmacokinetics Elsevier |
| topic |
ddc 570 fid BIODIV bkl 42.00 Elsevier Brain Elsevier Free drug hypothesis Elsevier BBB Elsevier Penetration Elsevier CNS Elsevier Drug design Elsevier Pharmacokinetics |
| topic_unstemmed |
ddc 570 fid BIODIV bkl 42.00 Elsevier Brain Elsevier Free drug hypothesis Elsevier BBB Elsevier Penetration Elsevier CNS Elsevier Drug design Elsevier Pharmacokinetics |
| topic_browse |
ddc 570 fid BIODIV bkl 42.00 Elsevier Brain Elsevier Free drug hypothesis Elsevier BBB Elsevier Penetration Elsevier CNS Elsevier Drug design Elsevier Pharmacokinetics |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l y ly z r zr |
| hierarchy_parent_title |
Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |
| hierarchy_parent_id |
ELV000457477 |
| dewey-tens |
570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000457477 |
| title |
Practical approaches to evaluating and optimizing brain exposure in early drug discovery |
| ctrlnum |
(DE-627)ELV048263524 (ELSEVIER)S0223-5234(19)30777-9 |
| title_full |
Practical approaches to evaluating and optimizing brain exposure in early drug discovery |
| author_sort |
Freeman, Burgess B. |
| journal |
Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |
| journalStr |
Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Freeman, Burgess B. |
| container_volume |
182 |
| class |
570 540 VZ BIODIV DE-30 fid 42.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Freeman, Burgess B. |
| doi_str_mv |
10.1016/j.ejmech.2019.111643 |
| dewey-full |
570 540 |
| title_sort |
practical approaches to evaluating and optimizing brain exposure in early drug discovery |
| title_auth |
Practical approaches to evaluating and optimizing brain exposure in early drug discovery |
| abstract |
Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. |
| abstractGer |
Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. |
| abstract_unstemmed |
Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| title_short |
Practical approaches to evaluating and optimizing brain exposure in early drug discovery |
| url |
https://doi.org/10.1016/j.ejmech.2019.111643 |
| remote_bool |
true |
| author2 |
Yang, Lei Rankovic, Zoran |
| author2Str |
Yang, Lei Rankovic, Zoran |
| ppnlink |
ELV000457477 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.ejmech.2019.111643 |
| up_date |
2024-07-06T18:22:07.113Z |
| _version_ |
1803854940328689664 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV048263524</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626021530.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200108s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejmech.2019.111643</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000788.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV048263524</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0223-5234(19)30777-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Freeman, Burgess B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Practical approaches to evaluating and optimizing brain exposure in early drug discovery</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Developing drugs for CNS related diseases continues to be one of the most challenging endeavors in drug discovery. This is at least in part related to the existence of the Blood Brain Barrier (BBB), a complex multicellular organization that provides selective access to required nutrients and hormones, while removing waste and restricting exposure to potential harmful toxins, pathogens, and xenobiotics. Consequently, designing and selecting molecules that can overcame this protection system are unique and critical aspects of the CNS drug discovery. Here we review modern CNS pharmacokinetic concepts and methods suitable for early drug discovery, and medicinal chemistry strategies towards molecules with optimal CNS exposure.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Brain</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Free drug hypothesis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BBB</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Penetration</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CNS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug design</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacokinetics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Lei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rankovic, Zoran</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Jose, Ajay ELSEVIER</subfield><subfield code="t">Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000457477</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:182</subfield><subfield code="g">year:2019</subfield><subfield code="g">day:15</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejmech.2019.111643</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.00</subfield><subfield code="j">Biologie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">182</subfield><subfield code="j">2019</subfield><subfield code="b">15</subfield><subfield code="c">1115</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4009705 |